<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04301739</url>
  </required_header>
  <id_info>
    <org_study_id>HLX10-013-TNBCneo</org_study_id>
    <nct_id>NCT04301739</nct_id>
  </id_info>
  <brief_title>to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)</brief_title>
  <official_title>A Randomized, Double-Blind, International Multi-Centre, Phase III Clinical Study to Evaluate Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-Blind,international multi-Centre, phase III clinical study
      to evaluate efficacy and safety of HLX10 in combination with chemotherapy versus placebo in
      combination with chemotherapy as neoadjuvant therapy and HLX10 versus placebo as adjuvant
      therapy in previously untreated and potentially resectable patients with TNBC and without
      distant metastasis.

      Eligible subjects in this study will be randomized to Arm A or Arm B at 2:1 ratio as follows:

      Arm A (HLX10 arm): HLX10 + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) → HLX10 +
      chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) → surgery → HLX10 (9
      cycles) Arm B (placebo arm): Placebo + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) →
      Placebo + chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) → surgery →
      Placebo (9 cycles) The three stratification factors for randomization include: lymph node
      metastasis (yes or no), size of primary tumor lesion (T1/T2 or T3/T4), asian population (yes
      or no).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 17, 2020</start_date>
  <completion_date type="Anticipated">April 9, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 7, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor assessment</measure>
    <time_frame>up till 5 years after the enroll</time_frame>
    <description>Pathological complete response (pCR) rate (ypT0/Tis, ypN0) (assessed by central pathology laboratory based on American Joint Committee on Cancer (AJCC) staging system)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">522</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>HLX10 + chemotherapy→ HLX10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLX10 + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) → HLX10 + chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) → surgery → HLX10 (9 cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + chemotherapy→ Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) → Placebo + chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) → surgery → Placebo (9 cycles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX10</intervention_name>
    <description>HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.</description>
    <arm_group_label>HLX10 + chemotherapy→ HLX10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide</intervention_name>
    <description>chemotherapeutics</description>
    <arm_group_label>HLX10 + chemotherapy→ HLX10</arm_group_label>
    <arm_group_label>Placebo + chemotherapy→ Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo + chemotherapy→ Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects histologically diagnosed with previously untreated TNBC (lack of human
             epidermal growth factor receptor-2 [HER2], estrogen receptor [ER], progesterone
             receptor expression as determined by the study site).

          2. Subjects who are judged as one of the following by the American Joint Committee on
             Cancer (AJCC) within 4 weeks prior to randomisation:

               1. T1c, N1-N2, M0

               2. T2, N0-N2, M0

               3. T3, N0-N2, M0

               4. T4a-c, N0-N2, M0.

          3. Major organs are functioning well

          4. Participant must keep contraception

        Exclusion Criteria:

          1. Subjects with any other active malignancy within 5 years prior to signing the informed
             consent form or at the same time. Localised tumours that have been cured such as basal
             cell carcinoma, squamous-cell skin cancer, superficial bladder carcinoma, and cervical
             cancer in situ are acceptable.

          2. Subjects who have received chemotherapy, targeted therapy, or radiotherapy within 12
             months prior to the initial dose of the investigational product.

          3. Subjects with a history of severe allergy to any monoclonal antibody or
             investigational product and its excipient.

          4. Pregnant or lactating women.

          5. Subjects with a known history of psychotropics abuse or drug abuse

          6. Subjects presenting other factors not suitable for participation as judged by the
             investigator.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tieshuang Chi, Master</last_name>
    <phone>+8618621117100</phone>
    <email>olivia_chi@henlius.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weizhen Liu, Bachelor</last_name>
    <phone>+8618801610708</phone>
    <email>weizhen_liu@henlius.com.cn</email>
  </overall_contact_backup>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Triple Negative Breast Cancer</keyword>
  <keyword>Previously Untreated</keyword>
  <keyword>Potentially Resectable</keyword>
  <keyword>Without Distant Metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

